Clinical Trial

mTOR as Mediator of Insulin Sensitivity Study

Recruiting
View on ClinicalTrials.gov →
Summary
The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise. This will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-01-31; most recent amendment 2024-05-14.
Trial Details
NCT Number NCT05233722
Lead Sponsor University of Copenhagen
Collaborators: Danish Diabetes Academy
Conditions Insulin Sensitivity
Enrollment 10 participants
Start Date 2022-02-10
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2024-05-16